No Association Between Trintellix and Proximal RTA
Trintellix (vortioxetine) is not associated with proximal renal tubular acidosis (type II RTA) based on FDA labeling and available evidence.
Evidence from FDA Drug Labeling
The official FDA prescribing information for Trintellix explicitly states that "TRINTELLIX has not been associated with any clinically important changes in laboratory test parameters in serum chemistry (except sodium), hematology and urinalysis" in controlled clinical trials 1. The only electrolyte abnormality documented is hyponatremia, not the metabolic acidosis or bicarbonate wasting characteristic of proximal RTA.
Understanding Proximal RTA Context
Proximal RTA is characterized by defective bicarbonate reabsorption in the proximal tubule, leading to:
- Normal anion gap metabolic acidosis
- Bicarbonate wastage in urine
- Often associated with Fanconi syndrome (phosphate, glucose, amino acid, and uric acid wasting) 2, 3
Common drug causes of proximal RTA include:
- Ifosfamide (most common chemotherapy agent) 4, 3
- Tenofovir and other antiretrovirals 3
- Valproic acid 3
- Carbonic anhydrase inhibitors 3
- Outdated tetracycline 5
- Amphotericin B 5
Clinical Implications
Vortioxetine's mechanism as a serotonin modulator does not involve renal tubular transport proteins (such as NBCe1 sodium-bicarbonate cotransporter or NaPi-II sodium-phosphate cotransporter) that are implicated in proximal RTA 2, 3. The drug's adverse effect profile centers on serotonergic effects (nausea, sexual dysfunction) and hyponatremia—not tubular dysfunction 1.
If a patient on Trintellix develops metabolic acidosis, look for alternative causes:
- Concomitant nephrotoxic medications
- Underlying autoimmune disease
- Plasma cell dyscrasias
- Other acquired causes of tubular dysfunction 6
The real-world safety data from 3,139 patients confirms vortioxetine is well-tolerated with nausea (8.9%) as the most common adverse event, with no reports of renal tubular dysfunction 7.